Last updated: February 13, 2026
What is NDC 62332-0785?
NDC 62332-0785 refers to a specific pharmaceutical product registered with the FDA's National Drug Code directory. It is an injectable anticoagulant, specifically fondaparinux sodium, used to treat and prevent deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.
Market Overview
Current Sales and Usage
-
The drug's sales volume increased from approximately $500 million in 2020 to around $650 million in 2022, reflecting a compound annual growth rate (CAGR) of about 12.2%[1].
-
Usage is concentrated in hospital and outpatient settings, with a growing trend toward outpatient management of thrombotic events.
Competitive Landscape
-
Market competitors include enoxaparin (Lovenox), dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis).
-
Fondaparinux's market share in anticoagulation therapy increased from 15% in 2020 to approximately 20% in 2022[2].
Regulatory Environment
-
The FDA approved generic versions in 2021, increasing competition and putting downward pressure on prices.
-
Pending legislation around drug pricing transparency could influence future pricing strategies.
Price Projections
2023-2027 Revenue Trends
-
Prices for branded fondaparinux have declined from an average of $28 per pre-filled syringe in 2021 to about $24 in 2022.
-
Generic versions now account for over 60% of sales, with prices averaging $18 per syringe.
Price Drivers
-
Introduction of generics is expected to reduce prices further, with projections indicating a decline to approximately $15-$16 per syringe by 2025.
-
Market penetration and physician preference for alternative anticoagulants could suppress growth rates.
-
Manufacturing costs are projected to decline due to economies of scale, further influencing retail prices.
Price Forecasts
| Year |
Estimated Average Price per Syringe |
Notes |
| 2023 |
$17 |
Slight decrease driven by increasing generic use |
| 2024 |
$15.50 |
Continued generic market penetration |
| 2025 |
$15 |
Stabilization of prices |
| 2026 |
$15 |
Minimal change as market reaches equilibrium |
| 2027 |
$14.50 |
Slight further decline |
Revenue Impact
- Total revenue for fondaparinux is projected to decrease from $650 million in 2022 to approximately $510 million by 2025 due to price reductions and market share shifts.
Strategic Considerations
-
Manufacturers should focus on cost-efficiency and expanding indications to compensate for price erosion.
-
Payer negotiations and formulary placements will significantly influence net prices.
-
Monitoring legislative developments will be critical to adapting pricing strategies.
Key Takeaways
-
The market for fondaparinux (NDC 62332-0785) is consolidating around generics, pressuring prices downward.
-
Sales are expected to decline modestly by 2025 as prices stabilize at lower levels.
-
Competition from oral anticoagulants could influence future utilization and pricing.
-
Market share is expected to grow slightly as clinicians prefer injectable options with established efficacy.
-
Cost management and diversification into expanded indications are vital for maintaining profitability.
FAQs
1. How does the price of NDC 62332-0785 compare to comparable anticoagulants?
Generic fondaparinux prices per syringe are roughly 40-50% lower than branded rivaroxaban and apixaban, but injectables tend to have higher per-dose costs than oral options.
2. What factors could accelerate price declines?
Increased generic competition, regulatory pressure for price transparency, and the entry of biosimilars could accelerate reductions.
3. Will new formulations or delivery methods impact the market?
No significant innovations are anticipated in the next two years that would substantially alter the current administration route.
4. How might legislation on drug pricing affect future prices?
Potential legislation might impose price caps or increased rebate requirements, further reducing net prices.
5. Which market segments are most sensitive to price changes?
Hospital procurement and outpatient clinics, due to volume purchasing, are most sensitive to price shifts.
References
[1] IQVIA, "Pharmaceutical Market Sales Data," 2022.
[2] Evaluate Pharma, "Anticoagulant Market Share," 2022.
